Kymera Therapeutics Stock Price on September 11, 2024
| KYMR Stock | USD 46.86 0.88 1.91% |
Below is the normalized historical share price chart for Kymera Therapeutics extending back to August 21, 2020. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Kymera Therapeutics stands at 46.86, as last reported on the 29th of November, with the highest price reaching 47.73 and the lowest price hitting 46.05 during the day.
If you're considering investing in Kymera Stock, it is important to understand the factors that can impact its price. Currently, Kymera Therapeutics is very steady. Kymera Therapeutics has Sharpe Ratio of 0.0212, which conveys that the firm had a 0.0212% return per unit of risk over the last 3 months. We have found twenty-three technical indicators for Kymera Therapeutics, which you can use to evaluate the volatility of the firm. Please verify Kymera Therapeutics' Mean Deviation of 2.37, risk adjusted performance of 0.0028, and Standard Deviation of 3.08 to check out if the risk estimate we provide is consistent with the expected return of 0.0658%.
As of 11/29/2024, Stock Based Compensation is likely to grow to about 45.3 M, while Total Stockholder Equity is likely to drop slightly above 278.6 M. . At this time, Kymera Therapeutics' Price Book Value Ratio is relatively stable compared to the past year. As of 11/29/2024, Price Earnings To Growth Ratio is likely to grow to 1.00, while Price Earnings Ratio is likely to drop (10.62). Kymera Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 21st of August 2020 | 200 Day MA 41.1094 | 50 Day MA 46.9081 | Beta 2.219 |
Kymera |
Sharpe Ratio = 0.0212
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | KYMR | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.1 actual daily | 27 73% of assets are more volatile |
Expected Return
| 0.07 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average Kymera Therapeutics is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kymera Therapeutics by adding it to a well-diversified portfolio.
Price Book 3.3988 | Enterprise Value Ebitda (9.49) | Price Sales 34.6596 | Shares Float 44 M | Wall Street Target Price 57.7647 |
Related Headline
Monte Rosa Headline on 11th of September 2024
Disposition of 541897 shares by Versant Venture Capital Vi, ... by Versant Venture Capital Vi, L.p.
Filed transaction by Monte Rosa Therapeutics 10 Percent Owner. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Kymera Therapeutics Valuation on September 11, 2024
It is possible to determine the worth of Kymera Therapeutics on a given historical date. On September 11, 2024 Kymera was worth 46.49 at the beginning of the trading date compared to the closed value of 44.77. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Kymera Therapeutics stock. Still, in general, we apply an absolute valuation method to find Kymera Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Kymera Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Kymera Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 46.56 | 46.93 | 44.95 | 46.88 | 220,688 | |
09/11/2024 | 46.49 | 46.90 | 44.65 | 44.77 | 362,959 |
| 44.70 | 46.03 | 44.20 | 44.72 | 251,621 |
| Backtest Kymera Therapeutics | | | Kymera Therapeutics History | | | Kymera Therapeutics Valuation | Previous | Next |
Kymera Therapeutics Trading Date Momentum on September 11, 2024
| On September 12 2024 Kymera Therapeutics was traded for 44.72 at the closing time. The top price for the day was 46.03 and the lowest listed price was 44.20 . The trading volume for the day was 251.6 K. The trading history from September 12, 2024 was a factor to the next trading day price decrease. The trading delta at closing time against the next closing price was 0.11% . The trading delta at closing time against the current closing price is 11.68% . |
Kymera Therapeutics Fundamentals Correlations and Trends
By evaluating Kymera Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Kymera Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Kymera financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Kymera Therapeutics Stock history
Kymera Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Kymera is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Kymera Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Kymera Therapeutics stock prices may prove useful in developing a viable investing in Kymera Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 58.4 M | 44.4 M | |
| Net Loss | -139.3 M | -132.4 M |
Kymera Therapeutics Quarterly Net Working Capital |
|
Kymera Therapeutics Stock Technical Analysis
Kymera Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Kymera Therapeutics Period Price Range
Low | November 29, 2024
| High |
0.00 | 0.00 |
Kymera Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Kymera Therapeutics November 29, 2024 Market Strength
Market strength indicators help investors to evaluate how Kymera Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Kymera Therapeutics shares will generate the highest return on investment. By undertsting and applying Kymera Therapeutics stock market strength indicators, traders can identify Kymera Therapeutics entry and exit signals to maximize returns
Kymera Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Kymera Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Kymera Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Kymera to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0028 | |||
| Jensen Alpha | (0.26) | |||
| Total Risk Alpha | (0.49) | |||
| Treynor Ratio | (0.01) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for Kymera Stock Analysis
When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.